Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $53.3952W HIGH $155.29
Volume
251.17 K
Value Traded
30.61 M
Short % Float
31.32%
Days to Cover
11.8
-1.31%Week
-12.88%1 Month
+7.47%3 Month
-32.59%6 Month
+500.95%5 Year
+358.46%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
1.30 B
EPS (TTM)
-9.39
P/E Ratio
-
Ent. Value
1.34 B
Total Shares
14.72 M
Float Shares
10.96 M
Insiders
25.55%
Institutions
87.96%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
PoA blends historical approval base rates, trial design score and FDA review track record.
INBX Catalyst Timeline
Dated clinical, regulatory and corporate events for Inhibrx Biosciences, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Inhibrx Biosciences, Inc.
95Total events
22Upcoming
37Tier-1 (high impact)
2024 to 2027Coverage
Upcoming catalysts 2
Event history 50
◆Oral PresentationINBRX-106Presentation
Webcast presentation to provide primary endpoint results from Phase 2 portion of HexAgon study
Head and Neck Squamous Cell Carcinoma (HNSCC)source ↗
●R&D DayPresentation
Inhibrx hosts live webcast presentation to discuss Phase 2 HexAgon results
▲Topline ReadoutINBRX-106Clinical Data
Primary endpoint results from randomized Phase 2 portion of HexAgon study of INBRX-106 plus pembrolizumab in first-line HNSCC
PD-L1 positive (CPS ≥ 20) metastatic or unresectable recurrent head and neck squamous cell carcinoma (HNSCC)source ↗
▲Primary Endpoint MetINBRX-106Clinical Data
INBRX-106 plus pembrolizumab met primary endpoint with 48.3% cORR vs 26.5% for pembrolizumab alone
PD-L1 positive (CPS ≥ 20) metastatic or unresectable recurrent head and neck squamous cell carcinoma (HNSCC)source ↗
▲Primary Endpoint MetINBRX-106Clinical Data
INBRX-106 plus pembrolizumab met primary endpoint with 48.3% cORR vs 26.5% for pembrolizumab alone in Phase 2 HexAgon study
head and neck squamous cell carcinoma (HNSCC)source ↗
▲Debt Royalty FinancingCorporate
Amended Loan Agreement with Oxford Finance, expanding total facility to $500.0 million
◆Trial InitiationINBRX-106Trial
Phase 3 portion of HexAgon study to begin in Q3 2026
first-line Head and Neck Squamous Cell Carcinoma (HNSCC)source ↗
◆Topline ReadoutINBRX-106Clinical Data
Plans to announce PFS data from randomized Phase 2 trial in HNSCC
head and neck squamous cell carcinoma (HNSCC)source ↗
●BLA SubmissionINBRX-109FiledRegulatory Filing
BLA submission for ozekibart in unresectable or metastatic conventional chondrosarcoma
conventional chondrosarcomasource ↗
▲FDA Filing AcceptedINBRX-109FiledRegulatory Filing
FDA acceptance of BLA for ozekibart
conventional chondrosarcomasource ↗
▲FDA Filing AcceptedINBRX-109FiledRegulatory Filing
FDA accepted BLA for ozekibart in conventional chondrosarcoma
conventional chondrosarcomasource ↗
◆Oral PresentationINBRX-106Presentation
Webcast presentation to provide interim results from randomized Phase 2 portion of HexAgon study
first-line HNSCCsource ↗
▲Interim AnalysisINBRX-106Trial
Interim Phase 2 data for INBRX-106 in combination with pembrolizumab vs pembrolizumab monotherapy in first-line HNSCC
first-line Head and Neck Squamous Cell Carcinoma (HNSCC)source ↗
◆Interim AnalysisINBRX-106Trial
Updated interim data from randomized Phase 2 portion of HexAgon study for INBRX-106 in combination with pembrolizumab
Head and Neck Squamous Cell Carcinoma (HNSCC)source ↗
◆Oral PresentationINBRX-109FiledPresentation
Webcast presentation to provide clinical update on ozekibart in combination with FOLFIRI in CRC
locally advanced or metastatic, unresectable colorectal cancersource ↗
▲Interim AnalysisINBRX-109FiledTrial
Updated interim data from Phase 1/2 study of ozekibart + FOLFIRI in CRC
colorectal cancersource ↗
●BLA SubmissionINBRX-109FiledRegulatory Filing
BLA submitted to FDA for ozekibart in conventional chondrosarcoma
conventional chondrosarcomasource ↗
◆Trial InitiationINBRX-106Trial
Initiate study in perioperative NSCLC later this quarter
non-small cell lung cancer (NSCLC) perioperative settingsource ↗
◆FDA Feedback ReceivedINBRX-109FiledFDA Meeting
FDA meeting to discuss accelerated approval for Ewing sarcoma and fourth-line colorectal cancer
Ewing sarcoma and fourth-line colorectal cancersource ↗
◆Topline ReadoutINBRX-109FiledClinical Data
PFS data maturity in colorectal cancer expansion cohort
colorectal cancersource ↗
◆Topline ReadoutINBRX-106Clinical Data
Announce ORR data from INBRX-106 Phase 2/3 trial in HNSCC in combination with pembrolizumab
HNSCCsource ↗
◆Interim AnalysisINBRX-109FiledTrial
Updated interim data from Phase 1/2 study evaluating ozekibart in combination with FOLFIRI in CRC
colorectal cancer (CRC)source ↗
◆Interim AnalysisINBRX-106Trial
Interim ORR data from randomized Phase 2/3 trial in HNSCC in combination with pembrolizumab
head and neck squamous cell carcinomasource ↗
◆Enrollment CompleteINBRX-109FiledTrial
Expected completion of enrollment in Ewing sarcoma trial
Ewing sarcomasource ↗
▲Trial InitiationINBRX-109FiledTrial
Initiated two additional Phase 1 cohorts in CRC
colorectal cancer (CRC)source ↗
▲Debt Royalty FinancingCorporate
Entered into First Amendment to Loan and Security Agreement with Oxford Finance, received $75M gross proceeds
◆Topline ReadoutINBRX-109FiledClinical Data
Data readout expected within next 12 months from press release date
unresectable or metastatic conventional chondrosarcomasource ↗
◆Topline ReadoutINBRX-106Clinical Data
Data readout expected within next 12 months from press release date
head and neck squamous cell carcinoma (HNSCC)source ↗
◆Oral PresentationINBRX-109FiledPresentation
Phase 1 Study of Ozekibart (INBRX-109) Combined With Irinotecan and Temozolomide in Adolescents and Adults With Ewing Sarcoma - Mini oral presentation at ESMO Sarcoma and Rare Cancers Congress
Ewing Sarcomasource ↗
◆Enrollment CompleteINBRX-106Trial
Expected completion of enrollment in Phase 2 portion for HNSCC
head and neck squamous cell carcinomasource ↗
●Enrollment UpdateINBRX-106Trial
Recruited 46 of 60 patients in Phase 2 portion for HNSCC
head and neck squamous cell carcinomasource ↗
◆Poster PresentationINBRX-109FiledPresentation
ozekibart (INBRX-109) exhibits anti-tumor activity in GBM models as monotherapy and in combination with TMZ
Glioblastoma (GBM)source ↗
◆Oral PresentationINBRX-109FiledPresentation
Detailed results to be presented at CTOS Annual Meeting
chondrosarcomasource ↗
◆Oral PresentationINBRX-109FiledPresentation
DR5 Agonist Clinical Data in Chondrosarcoma, Colorectal Cancer and Ewings Sarcoma
Chondrosarcoma, Colorectal Cancer, Ewings Sarcomasource ↗
▲Enrollment CompleteINBRX-106Trial
Completed enrollment of Phase 1/2 trial in NSCLC
checkpoint inhibitor refractory or relapsed non-small cell lung cancersource ↗
◆Timing GuidanceINBRX-109FiledPresentation
Data readout expected within next 12 months for ozekibart (INBRX-109)
unresectable or metastatic conventional chondrosarcomasource ↗
◆Timing GuidanceINBRX-106Presentation
Data readout expected within next 12 months for INBRX-106
head and neck squamous cell carcinomasource ↗
▲Topline ReadoutINBRX-109FiledClinical Data
Positive topline results from registrational ChonDRAgon study: met primary endpoint of PFS
chondrosarcomasource ↗
◆Enrollment UpdateINBRX-109FiledTrial
Expansion cohort initiated enrolling 44 patients in combination with FOLFIRI
colorectal cancersource ↗
◆Oral PresentationINBRX-109FiledPresentation
Webcast presentation of topline results from registrational ChonDRAgon study of ozekibart in chondrosarcoma
chondrosarcomasource ↗
▲Enrollment CompleteINBRX-109FiledTrial
Enrollment completed for ChonDRAgon trial with 206 patients
chondrosarcomasource ↗
▲Primary Endpoint MetINBRX-109FiledClinical Data
ChonDRAgon met primary endpoint of statistically significant PFS improvement
advanced or metastatic chondrosarcomasource ↗
◆Topline ReadoutINBRX-106Clinical Data
Initial Phase 2 data from randomized Phase 2/3 trial in HNSCC in combination with KEYTRUDA expected Q4 2025
head and neck squamous cell carcinomasource ↗
◆Interim AnalysisINBRX-106Trial
Interim data from Phase 1/2 trial in checkpoint inhibitor refractory/relapsed NSCLC expected Q4 2025
non-small cell lung cancersource ↗
◆Topline ReadoutINBRX-109FiledClinical Data
Data from expansion cohort anticipated
advanced or metastatic, unresectable colorectal adenocarcinomasource ↗
Past FDA Catalysts and PDUFA Decisions
How INBX actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2026-10-25 | ordastobart (INBRX-106) | Phase 2 data presentation | Phase 2 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
Pipeline Score
Pipeline Value
Valuation Signal
3
Drugs Scored
rNPV / MCap
Top Drug
Top 43%
Micro Cap(rank 283 of 657)
Percentile Rank
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| INBRX-109 Small moleculeNCT03715933 | Ewing Sarcoma | Phase 1 | RECRUITING | 411 | Jun 1, 2029 | ||||||
| INBRX-109 Small moleculeNCT04950075 | Conventional Chondrosarcoma | NDA/BLA | ACTIVE NOT_RECRUITING | 206 | Dec 1, 2026 | ||||||
| INBRX-106 Small moleculeNCT06295731 | Head and Neck Squamous Cell Carcinoma (HNSCC) | Phase 2 | ACTIVE NOT_RECRUITING | 410 | May 1, 2029 | ||||||
| INBRX-106 Small moleculeNCT04198766 | Solid Tumor | Phase 1 | RECRUITING | 340 | Jul 1, 2033 | ||||||
| INBRX-101/rhAAT-Fc Small moleculeCompletedNCT03815396 | Alpha-1 Antitrypsin Deficiency | Phase 1 | COMPLETED | 31 | Aug 18, 2022 |
Clinical Trial Results
Readouts, endpoints and source filings for every INBX program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| INBRX-106 | head and neck squamous cell carcinoma | Phase 2 | 2026-09-08 | c ORR combination: 48.3%; c ORR control: 26.5%; median PFS combination: 9.6 months; median PFS control: 4.9 months; six month PFS combination: 72.4%; six month PFS control: 42.8%; HPV positive c ORR combination: 80.0%; HPV positive c ORR control: 33.3%; HPV positive CR combination: 30.0%; HPV positive CR control: 0%; HPV positive six month PFS combination: 90.0%; HPV positive six month PFS control: 33.0%Read More | Inhibrx's INBRX-106 Nearly Doubles Response Rate and Achieves Interim Median PFS of 9.6 months in Phase 2 HNSCC Study First OX40 agonist to demonstrate clinical benefit in a randomized study INBRX-106 plus pembrolizumab delivers a 48.3% cORR and 72.4% of patients...Read More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Lappe MarkDirector, Officer (Chief Executive Officer) | Buy | 2,470 743,018 held | $84.07 | 10/14/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in INBX
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| PERCEPTIVE ADVISORS LLC | 1.8 % (-5.3 %) | 122.96 M | 1.30 M | -10.05% ( -144.94 K) |
INBX Institutional Ownership Trends
INBX Short Interest
Shares sold short, counted twice a month.
31.32%
Short % of Float
of tradable shares sold short
3.4M
Shares Sold Short
+1.2% vs prior count
11.8 Very high
Days to Cover
trading days of normal volume to buy every short share back
290.4K
Avg Daily Volume
the average used for days to cover
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-11-20 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How INBX ranks across every disease it competes in
Competitive Position is a premium feature
See how INBX ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialINBX News
INBXInhibrx Announces Participation in Upcoming Scientific Conferences
Inhibrx Biosciences, Inc. has announced its participation in several upcoming scientific conferences, including the ESMO Congress and the MSTS Annual Meeting. The presentations will focus on their investigational therapies, such as the OX40 agonist ordastobart and the DR5 agonist ozekibart. These events highlight Inhibrx's commitment to advancing its clinical pipeline.
Read more →INBX▼ -5.6%on this news
Inhibrx's INBRX-106 Nearly Doubles Response Rate and Achieves Interim Median PFS of 9.6 months in Phase 2 HNSCC Study
Inhibrx announced promising results from its Phase 2 study of INBRX-106 combined with pembrolizumab for head and neck squamous cell carcinoma. The combination achieved a confirmed objective response rate of 48.3% and a median progression-free survival of 9.6 months, significantly outpacing pembrolizumab alone. The company plans to expand the study to support potential accelerated approval.
Read more →INBX▼ -5.6%on this newsshared move
Inhibrx To Host Webcast Presentation to Provide Primary Endpoint Results for INBRX-106 Phase 2 First-Line HNSCC Study
Inhibrx Biosciences will host a live webcast on September 8, 2026, to present primary endpoint results from the Phase 2 HexAgon study of INBRX-106. This study evaluates the safety and efficacy of INBRX-106 in combination with pembrolizumab for first-line treatment of PD-L1 positive metastatic or unresectable recurrent Head and Neck Squamous Cell Carcinoma. Investors can join via a web link or phone.
Read more →INBX▼ -8.9%on this news
Inhibrx Reports Second Quarter 2026 Financial Results
Inhibrx Biosciences, Inc. reported its financial results for Q2 2026, highlighting significant funding and ongoing clinical trials. The company secured an additional $325 million through a loan amendment and is preparing to announce progression-free survival data from its Phase 2 trial in head and neck cancer. Despite these advancements, Inhibrx faced a net loss of $36.7 million and reported no revenue for the quarter.
Read more →INBXInhibrx Announces Amended Loan Agreement with Oxford Finance, Expanding Total Facility to $500.0 Million
Inhibrx Biosciences has amended its loan agreement with Oxford Finance, increasing its credit facility to $500 million. This includes a $100 million immediate funding and the potential for an additional $225 million. The funding aims to support the development of Inhibrx's clinical pipeline, including candidates INBRX-109 and INBRX-106.
Read more →INBXInhibrx Announces U.S. FDA Acceptance of BLA for Ozekibart in Patients with Conventional Chondrosarcoma No filing review issues identified by FDA with PDUFA goal date set for
Inhibrx has announced that the FDA accepted its Biologics License Application for ozekibart, which targets conventional chondrosarcoma, a rare and aggressive bone cancer. The FDA has not identified any issues with the filing, setting a goal date for decision on April 14, 2027. If approved, ozekibart would be the first systemic treatment available for patients with unresectable or metastatic forms of this cancer. The application is backed by positive trial results, indicating significant benefits in progression-free survival compared to placebo.
Read more →INBXInhibrx Reports First Quarter 2026 Financial Results
Inhibrx Biosciences reported its financial results for Q1 2026, highlighting ongoing clinical trials for INBRX-106 and ozekibart. The company announced an increase in cash reserves and plans to release key trial data later in the year. However, it also reported a net loss and rising interest expenses.
Read more →INBX▼ -5%on this news· ran to -19% by day 1shared move
Inhibrx Reports Interim Phase 2 Data for INBRX-106 in First-Line HNSCC; Initial Results Demonstrate Potential Costimulatory Benefit Over PD-1 Monotherapy
Inhibrx Biosciences announced positive interim results from the Phase 2 HexAgon study evaluating INBRX-106 in combination with pembrolizumab for first-line HNSCC. The combination arm showed a 22.6% increase in confirmed responses compared to the control. The treatment demonstrated robust T-cell activation and a manageable safety profile. The company plans to initiate Phase 3 trials in Q3 2026.
Read more →INBX▲ +7.9%on this newsshared move
Inhibrx To Host Webcast Presentation to Provide Clinical Update on INBRX-106 HexAgon Study in First Line HNSCC
Inhibrx Biosciences will host a live webcast on May 11, 2026, to present interim results from the Phase 2 HexAgon study. This study evaluates the safety and efficacy of INBRX-106 in combination with pembrolizumab for first-line treatment of PD-L1 positive metastatic or unresectable recurrent Head and Neck Squamous Cell Carcinoma. The webcast will be accessible for 60 days after the event.
Read more →INBXInhibrx Provides Clinical Update on Ozekibart (INBRX-109) in Late Line Colorectal Cancer
Inhibrx has provided an update on its Phase 1/2 study of ozekibart (INBRX-109) for colorectal cancer, revealing a 20% objective response rate and a median progression-free survival of 5.5 months. The drug demonstrated a manageable safety profile, with common side effects being mild. Inhibrx plans to discuss further development with the FDA, including potential first-line trials.
Read more →INBX▼ -6.6%on this news· ran to +36% by day 3shared move
Inhibrx To Host Webcast Presentation to Provide Clinical Update on Ozekibart (INBRX-109) in Late Line Colorectal Cancer
Inhibrx Biosciences will host a live webcast on April 21, 2026, to provide a clinical update on ozekibart (INBRX-109) in patients with advanced colorectal cancer. The presentation will discuss results from a Phase 1/2 study evaluating ozekibart in combination with FOLFIRI. Ozekibart has previously received Fast Track and orphan drug designations from the FDA for chondrosarcoma.
Read more →INBX▼ -5.6%on this newsshared move
Inhibrx Reports Fourth Quarter and Fiscal Year 2025 Financial Results
Inhibrx Biosciences reported its financial results for Q4 and fiscal year 2025, revealing a net loss of $32.8 million in Q4. The company has two ongoing clinical trials and plans to submit a Biologics License Application for ozekibart in early Q2 2026. Financial management appears to improve with reduced R&D and G&A expenses.
Read more →INBXInhibrx Announces Participation in Upcoming Scientific Conference
Inhibrx Biosciences, Inc. announced its participation in the ESMO Sarcoma and Rare Cancers Congress scheduled for March 12-14, 2026, in Lugano, Switzerland. The company will present a Phase 1 study of its DR5 agonist Ozekibart combined with Irinotecan and Temozolomide for treating Ewing Sarcoma. The presentation will be accessible via Inhibrx's investor website.
Read more →INBXInhibrx Biosciences Provides Progress Updates on the INBRX-106 Program and the Expansion Cohorts of the ozekibart (INBRX-109) Program
Inhibrx Biosciences provided updates on its INBRX-106 and ozekibart programs, highlighting progress in clinical trials for head and neck squamous cell carcinoma and non-small cell lung cancer. The company is nearing completion of patient enrollment in these trials and anticipates data maturity in 2026. Additionally, ozekibart's combination therapies have shown positive outcomes, with plans for FDA discussions regarding accelerated approval.
Read more →INBX▲ +6%on this news
Inhibrx Reports Third Quarter 2025 Financial Results
Inhibrx reported a net loss of $35.3 million for the third quarter of 2025. The company held $153.1 million in cash and cash equivalents at the end of the period. Ozekibart met its primary endpoint in a chondrosarcoma trial, prompting plans for a regulatory submission in 2026.
Read more →INBX▲ +102%on this news· ran to +172% by day 3
Inhibrx Biosciences Reports Positive Topline Results from its Registrational Trial of Ozekibart (INBRX-109) in Chondrosarcoma and Provides Updates on Colorectal Cancer and Ewing Sarcoma Expansion Cohorts
Inhibrx Biosciences reported positive topline results from its ChonDRAgon study, showing that ozekibart significantly improves median progression-free survival in patients with advanced chondrosarcoma. The study met its primary endpoint, demonstrating a 52% reduction in disease progression risk. Additionally, promising updates were shared regarding expansion cohorts for colorectal cancer and Ewing sarcoma, indicating potential for broader application of ozekibart.
Read more →INBX▼ -16%on this news· ran to +57% by day 3shared move
Inhibrx To Host Webcast Presentation of Topline Results from its Registrational Trial of Ozekibart (INBRX-109) in Chondrosarcoma and to Provide Updates on Colorectal Cancer and Ewing Sarcoma Expansion Cohorts
Inhibrx Biosciences, Inc. is set to host a live webcast on October 23, 2025, to present topline results from its registrational trial of ozekibart (INBRX-109) in patients with unresectable chondrosarcoma. The company will also provide updates on ongoing expansion trials for ozekibart in combination therapies for colorectal cancer and Ewing sarcoma. This presentation marks a key milestone in the clinical development of Inhibrx's product pipeline, highlighting its focus on innovative cancer treatments.
Read more →INBXInhibrx Reports Second Quarter 2025 Financial Results
Inhibrx reported a net loss of $28.7 million for the second quarter of 2025. Cash and cash equivalents stood at $186.6 million as of June 30. Revenue reached $1.3 million, up from $0.1 million in the prior year period. The company expects data readouts for its two clinical programs later this year.
Read more →INBXInhibrx Reports First Quarter 2025 Financial Results
Inhibrx Biosciences, Inc. reported its first quarter financial results for 2025, showcasing an increased cash balance following a successful financing round. The company now oversees two clinical programs, with expected data readouts for chondrosarcoma and colorectal cancer within this year. Research and development expenses decreased significantly compared to the previous year, while total operating expenses were also reduced. However, Inhibrx reported a net loss of $43.3 million for the quarter, highlighting persistent financial challenges as it continues to develop its clinical pipeline.
Read more →About Inhibrx Biosciences, Inc.
Headquarters11025 N. TORREY PINES ROAD, SUITE 140, LA JOLLA, CA, 92037
BIOPHARMAWATCH ELITE PLUS
Trade the next INBX catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime